More recently, Heike et al. [15] have reported that a combined immunohistochemical or fluorescence in situ hybridization (FISH)/immunohistochemical score, including MYC, BCL2, BCL6 protein expressions and MYC translocations, predicts outcome in DLBCL patients independent of the IPI following treatment with R-CHOP. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.